Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

06/09/2017 Thanks to MARES, SENER takes care of the physical well-being of the astronauts 30/08/2017 The Nanoworld Is Designed and Observed In and Nearby Barcelona Synchrotron Park 26/07/2017 ​The UAB Research Park: from the infinitely small to the infinitely big 19/07/2017 ​Barcelona Synchrotron Park’s key value: the environment 13/07/2017 ​SENER, 50 Years In Space! 04/07/2017 Barcelona Synchrotron Park Sponsors the Sixth Ideas Generation Program
15 16 17 18 19 20 21 22 23 24 25